Connect Total Assets vs Current Deferred Revenue Analysis
| CNTB Stock | USD 1.06 0.03 2.91% |
Connect Biopharma financial indicator trend analysis is way more than just evaluating Connect Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Connect Biopharma is a good investment. Please check the relationship between Connect Biopharma Total Assets and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Total Assets vs Current Deferred Revenue
Total Assets vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Connect Biopharma Total Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Connect Biopharma's Total Assets and Current Deferred Revenue is 0.59. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Connect Biopharma Holdings, assuming nothing else is changed. The correlation between historical values of Connect Biopharma's Total Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Connect Biopharma Holdings are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Total Assets i.e., Connect Biopharma's Total Assets and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.59 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Total Assets
Total assets refers to the total amount of Connect Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Connect Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Connect Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Connect Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, Connect Biopharma's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.73, whereas Tax Provision is forecasted to decline to about 114 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 641.0K | 1.0M | 988K | 803.8K | Interest Income | 622K | 10.7M | 2.7M | 3.5M |
Connect Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Connect Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Connect Biopharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 4.2M | 1.9M | 5.2M | 3.5M | 3.0M | 3.3M | |
| Total Current Liabilities | 27.4M | 5.8M | 18.0M | 15.9M | 24.3M | 17.9M | |
| Retained Earnings | (292.1M) | (164.1M) | (373.4M) | (463.8M) | (539.3M) | (512.4M) | |
| Accounts Payable | 22.8M | 3.8M | 12.7M | 11.9M | 7.7M | 8.3M | |
| Net Receivables | 1.2M | 265.2K | 7.4M | 235.9K | 51K | 48.5K | |
| Other Stockholder Equity | 42.5M | 7.4M | 628.8M | 7.2M | 628.5M | 660.0M | |
| Total Current Assets | 362.8M | 161.9M | 275.4M | 158.5M | 121.0M | 203.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share 0.438 | Return On Assets (0.12) | Return On Equity (0.18) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.